Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...
Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases. Number 4: February brought ...
The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat ...
February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
Number 4: Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its ...
Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy ...
Patients with inflammatory bowel disease (IBD) who switched from reference adalimumab (Humira) to a biosimilar under a mandatory nonmedical switching policy maintained long-term safety, efficacy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback